期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 65, 期 2, 页码 1171-1205出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c00981
关键词
-
资金
- SERB [EMR/2017/002702]
- Bristol-Myers Squibb, USA
The allosteric regulation of pyruvate kinase M2 (PKM2) plays a significant role in cellular activity and has potential applications in treating metabolic dysfunction and related conditions. This perspective article focuses on medicinal chemistry strategies for designing PKM2 inhibitors and activators with improved efficacy and selectivity.
The allosteric regulation of pyruvate kinase M2 (PKM2) affects the switching of the PKM2 protein between the high-activity and low-activity states that allow ATP and lactate production, respectively. PKM2, in its low catalytic state (dimeric form), is chiefly active in metabolically energetic cells, including cancer cells. More recently, PKM2 has emerged as an attractive target due to its role in metabolic dysfunction and other interrelated conditions. PKM2 (dimer) activity can be inhibited by modulating PKM2 dimer-tetramer dynamics using either PKM2 inhibitors that bind at the ATP binding active site of PKM2 (dimer) or PKM2 activators that bind at the allosteric site of PKM2, thus activating PKM2 from the dimer formation to the tetrameric formation. The present perspective focuses on medicinal chemistry approaches to design and discover PKM2 inhibitors and activators and further provides a scope for the future design of compounds targeting PKM2 with better efficacy and selectivity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据